- Citations, last 5 years
- 0
- Works, last 5 years
- 2
- h-index
- 6
- Scientists listed
- 1
- Grants since 2016
- 27
Grants received
2024–2026 · contract · N44
Design and Engineering of VesiVax HIV Immunogen Formulations
Samon Ho · Protein Express (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2024–2027 · contract · N01
VESIVAX TLR7 FORMULA
Samon Ho · Protein Express (United States) · funded by National Institutes of Health
2024–2026 · research · R44
Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2023–2025 · contract · N43
DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines
Sam Onho · Protein Express (United States) · funded by National Institutes of Health
2023–2024 · contract · N43
SBIR Diagnostic Method to Identify approved drugs as treatment options in individuals with rare cancer
Gitte Pedersen · Protein Express (United States) · funded by National Institutes of Health
2022–2023 · research · R43
Niclosamide Formulations for the Treatment of Influenza Infections
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2022–2023 · contract · N43
VesiVax HIVgp41e Vaccine Design
Gary Fuji · Protein Express (United States) · funded by National Institutes of Health
2022–2025 · research · R43
VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2022–2024 · contract · N44
Development of a VesiVax HIV Vaccine Formulation
Sam On Ho · Protein Express (United States) · funded by National Institutes of Health
2022–2024 · research · R43
VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2021–2023 · contract · N43
DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2021–2022 · contract · N43
Development of a VesiVax HIV Vaccine Formulation
Sam On Ho · Protein Express (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2020–2021 · contract · N43
Design and Engineering of VesiVax HIV Immunogen Formulations
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2020–2021 · contract · N43
Evaluation of Conjugated VesiVax Formulations for HIV Vaccines
Sam On Ho · Protein Express (United States) · funded by National Institutes of Health
2019–2021 · contract · N43
Evaluation of VesiVax Adjuvant Formulations for HIV Vaccines
Sam Ho · Protein Express (United States) · funded by National Institutes of Health
2018–2019 · research · R43
Development of an engineered CCL20 protein as a lead therapeutic molecule for Psoriasis
Anthony E Getschman · Protein Express (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
Mucosal Vaccines Against Enteric Infections
(Contact) · Protein Express (United States) · funded by National Institutes of Health
2017–2019 · grant · Standard Grant
SBIR Phase II: A Serious Game for Job Skills
Marc Zimmerman · Protein Express (United States) · funded by National Science Foundation
2017–2018 · contract · N01
DELIVERY OF SELF-REPLICATING HIV VACCINES USING IN VITRO RECONSTITUTED VIRUS-LIKE PARTICLES
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2017–2019 · research · R43
VesiVax® Peanut Allergy Immunotherapy
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Optimization of VesiVax® Lipidated Tucaresol Formulations
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
2016–2018 · contract · N01
DEVELOPMENT OF A WEST NILE VIRUS VACCINE
Gary Fujii · Protein Express (United States) · funded by National Institutes of Health
